QuadMedicine, Inc. (KOSDAQ:464490)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Biotechnology (Startups)	10.70B	9.30B	1.01B
Biotechnology (Startups) Growth	14.99%	819.58%	-
Total	10.70B	9.30B	1.01B
Total Growth	14.99%	819.58%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
South Korea	10.18B	8.46B	1.01B
South Korea Growth	20.41%	735.95%	-
Europe	514.05M	846.11M	-
Europe Growth	-39.25%	-	-
Total	10.70B	9.30B	1.01B
Total Growth	14.99%	819.58%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 27, 2026

Data Sources Report a data error